Side effects of pharmacotherapy on lipid levels

Česká verzia

Authors: Š. Svačina
Authors place of work: III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in the journal: Vnitř Lék 2007; 53(4): 408-411
Category: Reviews

Summary

Modern and effective pharmacotherapy for hypolipidemia usually compensates the negative effect of certain groups of drugs on lipid levels. Nevertheless, the fact that some psychotropic, antiepileptic, antihypertensive or hormonal drugs may have a certain negative impact should be taken into consideration. The article provides an overview of some of the drug groups provoking dyslipidemia, as well as an overview of drugs with a positive effect on dyslipidemia.

Key words:
cholesterol – triglycerides – metabolic syndrome – psychotropic drugs – antiepileptic drugs – antihypertensive drugs – hormonal replacement therapy – contraception – antidiabetic drugs

Zdroje

1. Papakostas GI et al. Serum cholesterol in treatment-resistant depression. Neuropsychobiology 2003; 47: 146-151.

2. Mahadik SP, Evans DR. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr Clin North Am 2003; 26: 85-102.

3. Peters H et al. Serum cholesterol level comparison: control subjects, anxiety disorder patients, and obsessive-compulsive disorder patients. Can J Psychiatry 2002; 47: 557-562.

4. Almeida-Montes LG et al. Relation of serum cholesterol, lipid, serotonin and tryptophan levels to severity of depression and to suicide attempts. J Psychiatry Neurosci 2000; 25: 371-377.

5. Svačina Š. Metabolické účinky psychofarmak. Praha: Triton 2004.

6. Melkerssson KI et al. Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizofrenia or related psychoses. J Clin Psychiatry 2000; 61: 742-749.

7. Almeras A et al. Development of an atheriogenic metabolic risk. Profile associated with the use of some atypical neuroleptics. Proc North Am Assoc Obesity 2001; 54: 46.

8. Bettinger TL et al. Olanzapine induced glucose dysregulation. Ann Pharmacother 2000; 34: 865-867.

9. Atmaca M et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64: 598-604.

10. Cohen S et al. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J Clin Psychiatry 2003; 64: 60-62.

11. Lindenmayer JP et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290-296.

12. Šmahelová A. Akutní komplikace diabetu. Praha: Triton 2006.

13. Wetterling T. Hyperlipidemia - side-effect of the treatment with an atypical antipsychotic (zotepine)? Psychiatr Prax 2002; 29: 438-440.

14. McGavin JK, Goa KL. Aripiprazole. CNS Drugs 2002; 16: 779-786.

15. Appolinario JC et al. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit 2004; 10: MT50-MT52.

16. Šmahelová A et al. Significance of plant sterols in diabetes. Vnitř Lék 2004; 50: 147-152.

17. Bramswig S et al. Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults. Am J Physiol Heart Circ Physiol 2002; 282: H704-H716.

18. Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996; 93: 1976-1980.

19. Sonawalla SB et al. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics 2002; 43: 310-316.

20. de Zwaan M, Nutzinger DO. Effect of fluvoxamine on total serum cholesterol levels during weight reduction. J Clin Psychiatry 1996; 57: 346-348.

21. Yang CC, Jick SS, Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 2003; 163: 1926-1932.

22. Svačina Š et al. Metabolický syndrom. Praha: Triton 2006.

23. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998; 11: 1258-1265.

24. Svačina Š. Hypertenze při obezitě a diabetu. Praha: Triton 2006.

25. Ernsberger P. The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. Ann N Y Acad Sci 2003; 1009: 251-261.

26. Scemama M, Fevrier B, Beucler I et al. Effects of rilmenidine (hyperium) on lipid balance in hyperlipidemic hypertensive patients. Randomized, controlled, double-blind 8-week study vs captopril in parallel groups. Ann Cardiol Angeiol (Paris) 1996; 45: 595-601.

27. Widimsky J, Sirotiakova J. Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome. Curr Med Res Opin 2006; 22: 1287-1294.

28. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005; 71: 409-416.

29. Banaszewska B et al. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial J Clin Endocrinol Metab 2007; 92: 456-461.

30. Salpeter SR et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006; 8: 538-554.

31. Engin-Ustun Y et al. Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: a randomized, placebo-controlled clinical trial. Gynecol Endocrinol 2006; 22: 676-679.

32. Alagozlu H et al. Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis Clin Drug Investig 2006; 26: 297-302.

33. Gillett MJ, Burnett JR, Yeap D. Clomiphene-associated combined hyperlipidemia: a case report. J Reprod Med 2006; 51: 587-590.

34. Tugrul S et al. Comparison of two forms of continuous combined hormone replacement therapy with respect to metabolic effects Arch Gynecol Obstet 2007; 275: 335-339.

35. Haluzík M, Svačina Š. Metabolický syndrom a jaderné receptory PPAR. Praha: Grada 2005.

36. Haberbosch W. Effects of Thiazolidinediones on Dyslipidemia in Patients with Type 2 Diabetes. Are All Equally Vasoprotective? Herz 2007; 32: 51-57.

37. Chappuis B et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab Res Rev 2007; 8: Epub.

38. Rosenstock J et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007; 30: 217-223.

39. Kothare PA et al. Exenatide effects on statin pharmacokinetics and lipid response. Int J Clin Pharmacol Ther 2007; 45: 114-120.